
Nura Bio raises $73.8m, advances pipeline of SARM1 inhibitors
Nura Bio has completed a $73.8 million Series B financing round as it advances its pipeline of SARM1 inhibitors. The financing, led by The Column Group, is set to fund the development of Nura Bio’s clinical pipeline, including the Phase Ib/IIa study of NB-4746, an oral, brain-penetrant SARM1… Read More














